ALK and non-small cell lung carcinoma: As chemotherapy has limited efficacy in ALK+ NSCLC after failure of a second-generation ALK TKI, combination therapy with ALK TKI and chemotherapy has been proposed in ALK+ NSCLC refractory to at least one second-generation ALK TKI.